Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.
| 0.9151 | |
| 0.8797 | |
| - | |
| 0.9151 | |
| 0.8699 | |
| 0.675-5.64 | |
| 76 591 K | |
| 88 544 K | |
| 0 | |
| -0.81 | |
| 0.865 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
It was a low-key week for the biotech sector with no major updates. Regulatory and pipeline updates from a few players were in focus. Recap of the Week’s Most Important Stories: Vertex, CRSP Gene ...
Allakos Inc. (ALLK) has been beaten down lately with too much selling pressure. While the stock has lost 61.4% over the past four weeks, there is light at the end of the tunnel as it is now in oversol...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
